KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Accured Expenses: 2024-2025

Historic Change in Accured Expenses for AbCellera Biologics (ABCL) over the last 2 years, with Sep 2025 value amounting to $5.1 million.

  • AbCellera Biologics' Change in Accured Expenses rose 22.23% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year change of. This contributed to the annual value of $10.6 million for FY2024, which is 170.41% up from last year.
  • Latest data reveals that AbCellera Biologics reported Change in Accured Expenses of $5.1 million as of Q3 2025, which was up 228.45% from -$3.9 million recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Change in Accured Expenses registered a high of $6.6 million during Q4 2024, and its lowest value of -$4.9 million during Q1 2024.
  • Its 2-year average for Change in Accured Expenses is $1.2 million, with a median of $4.1 million in 2024.
  • Within the past 5 years, the most significant YoY rise in AbCellera Biologics' Change in Accured Expenses was 30.11% (2025), while the steepest drop was 183.13% (2025).
  • AbCellera Biologics' Change in Accured Expenses (Quarterly) stood at $6.6 million in 2024, then climbed by 22.23% to $5.1 million in 2025.
  • Its Change in Accured Expenses stands at $5.1 million for Q3 2025, versus -$3.9 million for Q2 2025 and -$3.4 million for Q1 2025.